| Title | First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. |
| Publication Type | Journal Article |
| Year of Publication | 2011 |
| Authors | Ciaranello, Andrea L., Shahin Lockman, Kenneth A. Freedberg, Michael Hughes, Jennifer Chu, Judith Currier, Robin Wood, Charles B. Holmes, Sandy Pillay, Francesca Conradie, James McIntyre, Elena Losina, and Rochelle P. Walensky |
| Corporate Authors | CEPAC-International and OCTANE Investigators |
| Journal | AIDS (London, England) |
| Volume | 25 |
| Issue | 4 |
| Pagination | 479-92 |
| Date Published | 2011 Feb 20 |
| ISSN | 1473-5571 |
| Keywords | Adult, Anti-HIV Agents, Cost-Benefit Analysis, Female, HIV Infections, Humans, Infant, Newborn, Infectious Disease Transmission, Vertical, Life Expectancy, Lopinavir, Male, Nevirapine, Pregnancy, Pyrimidinones, Ritonavir, South Africa, Treatment Outcome |
| Abstract | The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine. |
| DOI | 10.1111/j.1524-4733.2010.00763.x |
| Alternate Journal | AIDS |
